Reported Saturday, Merck Reports KEYTRUDA Plus WELIREG Reduced Risk Of Disease Recurrence Or Death By 28% Vs KEYTRUDA Alone In Adjuvant RCC, FDA Accepts Priority Review Supplemental Applications

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage disease, regardless of tumor type, to demonstrate a disease-free survival improvement compared to KEYTRUDA

Based on these data, the U.S. FDA has accepted for priority review supplemental applications for WELIREG in combination with KEYTRUDA or KEYTRUDA QLEX™ for the adjuvant treatment of certain patients with RCC